Conformational dynamics of the EGFR kinase domain reveals structural features involved in activation

Proteins: Structure, Function and Bioinformatics

Volumn 76, Issue 2, 2009, Pages 375-386

  Papakyriakou, Athanasios ^a   Vourloumis, Dionisios ^a   Tzortzatou Stathopoulou, Fotini ^b   Karpusas, Michael ^b  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Epidermal growth factor receptor; ErbB1; HER1; L834R; L858R; Mutations; Targeted molecular dynamics simulations

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; PROTEIN KINASE;

ARTICLE; CANCER RESEARCH; CONFORMATION; CRYSTAL STRUCTURE; DIMERIZATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; SIMULATION;

COMPUTATIONAL BIOLOGY; DIMERIZATION; ENZYME ACTIVATION; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 67650236882     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.22353     Document Type: Article

References (41)

1. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53.
2. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37 (Suppl 4):S3-S8.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
4. Marshall J. Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 2006;107:1207-1218.
5. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007;14:295-304.
6. Tice DA, Biscardi JS, Nickles AL, Parsons SJ. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 1999;96:1415-1420.
7. Landau M, Ben-Tal N. Dynamic equilibrium between multiple active and inactive conformations explains regulation and oncogenic mutations in ErbB receptors. Biochim Biophys Acta 2008;1785:12-31.
8. Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265-46272.
9. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006;125:1137-1149.
10. Gu D, Scaringe WA, Li K, Saldivar JS, Hill KA, Chen Z, Gonzalez KD, Sommer SS. Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature. Hum Mutat 2007;28:760-770.
11. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
12. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
13. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008;26:1742-1751.
14. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 2007;11:217-227.
15. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004;64:6652-6659.
16. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell 2002;109:275-282.
17. Kornev AP, Haste NM, Taylor SS, Eyck LF. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 2006;103:17783-17788.
18. Karplus M, Brunger AT, Elber R, Kuriyan J. Molecular dynamics: applications to proteins. Cold Spring Harb Symp Quant Biol 1987;52:381-390.
19. Karplus M, Kuriyan J. Molecular dynamics and protein function. Proc Natl Acad Sci USA 2005;102:6679-6685.
20. Vajpai N, Strauss A, Fendrich G, Cowan-Jacob SW, Manley PW, Grzesiek S, Jahnke W. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem 2008;283:18292-18302.
21. Schlitter J, Engels M, Kruger P. Targeted molecular dynamics: a new approach for searching pathways of conformational transitions. J Mol Graph 1994;12:84-89.
22. Ma J, Sigler PB, Xu Z, Karplus M. A dynamic model for the allosteric mechanism of GroEL. J Mol Biol 2000;302:303-313.
23. Levinson NM, Kuchment O, Shen K, Young MA, Koldobskiy M, Karplus M, Cole PA, Kuriyan J. A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol 2006;4:e144.
24. Perdih A, Kotnik M, Hodoscek M, Solmajer T. Targeted molecular dynamics simulation studies of binding and conformational changes in E. coli MurD. Proteins 2007;68:243-254.
25. Zou J, Wang YD, Ma FX, Xiang ML, Shi B, Wei YQ, Yang SY. Detailed conformational dynamics of juxtamembrane region and activation loop in c-Kit kinase activation process. Proteins 2008;72:323-332.
26. Swift RV, McCammon JA. Catalytically requisite conformational dynamics in the mRNA-capping enzyme probed by targeted molecular dynamics. Biochemistry 2008;47:4102-4111.
27. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nat Struct Biol 2003;10:980.
28. Case DA, Cheatham TE, III, Darden T, Gohlke H, Luo R, Merz KM, Jr, Onufriev A, Simmerling C, Wang B,Woods RJ. The Amber biomolecular simulation programs. J Comput Chem 2005;26:1668-1688.
29. Bashford D, Karplus M. pKa's of ionizable groups in proteins: atomic detail from a continuum electrostatic model. Biochemistry 1990;29:10219-10225.
30. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 1995;117:5179-5197.
31. Tsui V, Case DA. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers 2001;56:275-291.
32. Jorgensen WL, Chandrasekhar J, Madura J, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983;79:926-935.
33. Miyamoto S, Kollman PA. Settle: an analytical version of the SHAKE and RATTLE algorithm for rigid water models. J Comput Chem 1992;13:952-962.
34. Cheatham TEI, Miller JL, Fox T, Darden TA, Kollman PA. Molecular dynamics simulations on solvated biomolecular systems: The particle mesh Ewald method leads to stable trajectories of DNA. RNA, and proteins. J Am Chem Soc 1995;117:4193-4194.
35. Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys 1984;81:3684-3690.
36. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996;14:33-38, 27-38.
37. Stein RA, Staros JV. Insights into the evolution of the ErbB receptor family and their ligands from sequence analysis. BMC Evol Biol 2006;6:79.
38. Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995;376:313-320.
39. Liu B, Bernard B, Wu JH. Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations. Proteins 2006;65:331-346.
40. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, Park F, Haley JD, Gibson N, Sliwkowski MX. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006;66:8163-8171.
41. Brignola PS, Lackey K, Kadwell SH, Hoffman C, Horne E, Carter HL, Stuart JD, Blackburn K, Moyer MB, Alligood KJ, Knight WB, Wood ER. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains: Demonstration of differential sensitivity to kinase inhibitors. J Biol Chem 2002;277:1576-1585.